2. Cell Cycle/DNA Damage PI3K/Akt/mTOR
  3. ATM/ATR
  4. Tuvusertib

Tuvusertib  (Synonyms: M1774; ATR inhibitor 1)

Cat. No.: HY-111451 Purity: 99.75%
COA Handling Instructions

Molarity Calculator

Tuvusertib (M1774; ATR inhibitor 1) is a selective and orally active ATR inhibitor extracted from patent WO2015187451A1, compound I-l, with a Ki value below 1 μΜ.

For research use only. We do not sell to patients.

Tuvusertib Chemical Structure

Tuvusertib Chemical Structure

CAS No. : 1613200-51-3

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 187 In-stock
Solution
10 mM * 1 mL in DMSO USD 187 In-stock
Solid
5 mg USD 170 In-stock
10 mg USD 270 In-stock
25 mg USD 500 In-stock
50 mg USD 700 In-stock
100 mg USD 970 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Tuvusertib Related Antibodies

Top Publications Citing Use of Products

View All ATM/ATR Isoform Specific Products:

View All Isoforms
ATM ATR

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tuvusertib (M1774; ATR inhibitor 1) is a selective and orally active ATR inhibitor extracted from patent WO2015187451A1, compound I-l, with a Ki value below 1 μΜ[1].

IC50 & Target

Ki: less than 1 uM[1]
In Vitro

Tuvusertib (0-2 μM, 24 h) induces cell death and cell apoptosis in myeloma cells (such as U266 and OPM2 cells)[2].
Tuvusertib (0-5 μM, 16 or 24 h) inhibits STAT3 p-Y705 phosphorylation and down-regulates STAT3 downstream targets (c-MYC) in U266 and OPM2 cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tuvusertib Related Antibodies

Western Blot Analysis[2]

Cell Line: U266 and OPM2 cells
Concentration: 0-2 μM
Incubation Time: 24 h
Result: Increased level of γH2A.X, cleavage of caspase-3, and cleavage of PARP.
Clinical Trial
Molecular Weight

370.32

Formula

C16H12F2N8O
CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(C1=C2N=CC(F)=CN2N=C1N)NC3=C(C4=CN=CN4C)C(F)=CN=C3
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 5 mg/mL (13.50 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.7004 mL 13.5018 mL 27.0037 mL
5 mM 0.5401 mL 2.7004 mL 5.4007 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 99.77%

COA (256 KB) HNMR (271 KB) LCMS (264 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.7004 mL 13.5018 mL 27.0037 mL 67.5092 mL
5 mM 0.5401 mL 2.7004 mL 5.4007 mL 13.5018 mL
10 mM 0.2700 mL 1.3502 mL 2.7004 mL 6.7509 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tuvusertib Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tuvusertib1613200-51-3M1774 ATR inhibitor 1M 1774M-1774ATR inhibitor1ATR inhibitor 1ATR inhibitor-1ATM/ATRAtaxia telangiectasia mutatedATM and RAD3 relatedU266OPM2anticancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tuvusertib
Cat. No.:
HY-111451
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.